This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In this issue of Neurology, two articles address important issues in the treatment of myasthenia gravis (MG).1,2 Gronseth and Barohn review the role of thymectomy1 and the Task Force of the Medical Scientific Advisory Board of the MG Foundation of America outlines a comprehensive grading system for classifying and following patients.2 Although these two articles are different in their approach and scope, both are important pieces of work that represent significant contributions to the literature on MG.
MG represents one of the great medical triumphs of the last half century. In 1960, Simpson first proposed that MG was an autoimmune disease and hypothesized that it resulted from an antibody-dependent block in neuromuscular transmission. Investigations in the 1970s demonstrated the deficiency of acetylcholine receptors at the neuromuscular junction in MG, the production of animal models by immunization with acetylcholine receptors, the passive transfer of the disease between species with immunoglobulin G, and the presence of antibodies to acetylcholine receptors in most patients with MG.3 Subsequently, the immunopathogenic and electrophysiologic mechanisms involved in the disease were elucidated.
Coincident with these discoveries, effective treatments were developed, including acetylcholinesterase inhibitors in the 1950s, and by 1970, prednisone and other immunosuppressive medications were available. In the 1970s, thymectomy—first described as a treatment modality in 1936—became an increasingly accepted form of therapy. In the 1980s, both plasma exchange and intravenous immunoglobulin were used to treat MG, particularly in patients with life-threatening illness.
However, problems and questions remain. …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
